Drug Profile
Anti-GD2 chimeric antigen receptor T cell therapy - Bellicum Pharmaceuticals
Alternative Names: Anti-GD2 CAR transduced T cells - Bellicum Pharmaceuticals; Anti-GD2 CIDeCAR T cell therapy - Bellicum Pharmaceuticals; Anti-GD2 third party CAR T cell therapy - Bellicum Pharmaceuticals; GD2-CAR.OX40.28.z.ICD9Latest Information Update: 02 Jun 2022
Price :
$50
*
At a glance
- Originator Bellicum Pharmaceuticals
- Developer National Cancer Institute (USA)
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 30 May 2022 Discontinued - Phase-I for Solid tumours (In adolescents, In children, Metastatic disease, Recurrent, Second-line therapy or greater, In adults) in USA (IV) (Takeda pipeline, June 2022)
- 08 Apr 2022 Efficacy and adverse events data from a phase I trial in Solid tumours presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
- 28 Apr 2018 No recent reports of development identified for phase-I development in Solid-tumours(In adolescents, In children, Metastatic disease, Recurrent, Second-line therapy or greater, In adults) in USA (IV, Infusion)